Loading...
AREV Life Sciences Global Corp.
AREV.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.09
CA$0.00(0.00%)

Over the past four quarters, AREV Life Sciences Global Corp. demonstrated steady revenue growth, increasing from $7209.00 in Q4 2022 to $0.00 in Q3 2023. Operating income reached -$27980.00 in Q3 2023, maintaining a consistent N/A margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$14142.00, reflecting operational efficiency. Net income rose to -$28925.00, with EPS at -$0.001. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan